Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

327P - Predictors of progression-free survival in patients with metastatic breast cancer receiving palbociclib with letrozole

Date

16 Sep 2021

Session

ePoster Display

Presenters

Roya Behrouzi

Citation

Annals of Oncology (2021) 32 (suppl_5): S457-S515. 10.1016/annonc/annonc689

Authors

R. Behrouzi1, S. Moon2, D. Eaton2

Author affiliations

  • 1 Medical Oncology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 2 Medical Oncology, University Hospitals of Morecambe Bay NHS Foundation Trust, LA1 4RP - Lancaster/GB
More

Abstract 327P

Background

Palbociclib with endocrine therapy is a first line treatment for patients with estrogen receptor positive (ER+)/ human epidermal growth factor receptor negative (HER2-) metastatic breast cancer (MBC). There is limited data regarding factors which predict progression-free survival (PFS) in patients receiving this treatment.

Methods

Patients with ER+/HER2- MBC starting palbociclib with letrozole at a UK cancer centre from May 2017 - Dec 2020 were retrospectively identified. Baseline patient and treatment characteristics were obtained from electronic records. PFS was calculated from date of MBC diagnosis to Mar 2021.

Results

61 patients were identified with mean age 63 ± 1.3 years. 2 were male. 58 (95%) were treatment naive and 3 (5%) had received a single chemotherapy line. The table shows further data. Median PFS was 27.9 months (95% CI 21.3-34.5). Patients with performance status (PS) 0 (HR 0.32, 95% CI 0.13-0.80, p=0.010), no liver metastases (HR 0.46, 95% CI 0.21-1.00, p=0.046) or bone only (non-visceral) metastases (HR 0.36, 95% CI 0.14-0.95, p=0.034) had a longer PFS than patients without these characteristics. Median PFS was 17.2 months (95% CI 6.9-27.5) in patients with liver metastases compared to 30.7 months (95% CI 23.5-37.9) in patients without. Patients with bone only metastases or PS 0 did not reach median PFS. Age, comorbidities, menopause, histology, grade, number of metastatic sites, de novo vs recurrence, dose reduction or toxicity did not predict PFS (p>0.05). In patients with recurrence, previous chemotherapy, mastectomy, relapse on endocrine treatment or relapse within 5 years were not predictive of PFS (p>0.05). Table: 327P

Baseline characteristics (n=61) Treatment characteristics
PS 0 = 22 (36%)1 = 32 (53%)2 = 7 (12%) Maximum palbociclib dose reduction n=61 0 = 17 (28%)20% = 25 (41%)40% = 19 (31%)
Menopause Yes = 52 (85%)No =7 (11%)N/A = 2 (3%) Reason for reduction n=44 Toxicity = 41 (93%) Comorbidity = 3 (7%)
Tumour Grade 1 = 5 (8%)2 = 35 (57%)3 = 17 (28%)Unknown = 4 (7%) Dose limiting toxicity n=41 Neutropenia = 30 (73%)Mucositis = 4 (10%)Fatigue = 2 (5%)Other = 5 (12%)
Metastatic sites Bone only = 18 (30%)Visceral = 43 (70%)Liver = 16 (26%) Reason for stopping n=29 Progression = 22 (76%)Toxicity = 4 (14%)Death = 3 (10%)
Disease type Recurrence = 44 (72%)De Novo = 17 (28%) Cause of death n=14 Breast cancer = 14

Conclusions

Median PFS was similar to that in the PALOMA-2 study. PS ≥1, liver metastases or any visceral metastases were associated with a significantly shorter PFS. This suggests PS and metastatic pattern are important predictors of PFS and could be used to influence frequency of monitoring in patients with MBC receiving palbociclib.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings